|
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
|
||
|
SEC
FILE NUMBER
1-12632
|
||
|
CUSIP
NUMBER
40048P104
|
|
(Check
one):
|
[ ]
Form
10-K [X]
Form
20-F [ ]
Form
11-K [ ]
Form
10-Q [ ]
Form
10-D [ ] Form
N-SAR [
] Form N-CSR
|
||
| For Period Ended: |
December 31, 2008
|
|
|
|
Transition Report on Form
10-K
|
|||
|
Transition Report on Form
20-F
|
|||
|
Transition Report on Form
11-K
|
|||
|
Transition Report on Form
10-Q
|
|||
|
Transition Report on Form
N-SAR
|
|||
|
For
the Transition Period
Ended:_______________________
|
|||
|
Nothing
in this form shall be construed to imply that the Commission has verified
any information contained
herein.
|
|
If the notification relates to a
portion of the filing checked above, identify the Item(s) to which the
notification relates:
|
|
PART
I — REGISTRANT INFORMATION
Grupo
Casa Saba, S.A.B. de C.V.
|
|
Full
Name of Registrant
Grupo
Casa Autrey, S.A. de C.V.
|
|
Former
Name if Applicable
Paseo
de la Reforma No. 215
|
|
Address
of Principal Executive Office (Street and
Number)
Colonia
Lomas de Chapultepec, Mexico, D.F. 11000
|
|
City,
State and Zip Code
|
|
(a)
|
The
reason described in reasonable detail in Part III of this form could not
be eliminated without unreasonable effort or expense
|
|
|
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K,
Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will
be filed on or before the fifteenth calendar day following the prescribed
due date; or the subject quarterly report or transition report on Form
10-Q or subject distribution report on Form 10-D, or portion thereof, will
be filed on or before the fifth calendar day following the prescribed due
date; and
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has
been attached if applicable.
|
|
(1)
|
Name
and telephone number of person to contact in regard to this
notification
|
|
Sandra
Yatsko
|
+52
55
|
5284
6698
|
||
|
(Name)
|
(Area
Code)
|
(Telephone
Number)
|
|
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the
preceding
12 months or for such shorter period that the registrant was required to
file such report(s) been filed ? If answer is no, identify
report(s). Yes [X] No
[ ]
|
|
(3)
|
Is
it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be
included
in the subject report or portion thereof ? Yes [X] No
[ ]
|
|
If
so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
The
Company made significant investments in its private pharmaceuticals
business division, particularly in its retail pharmacy business in Mexico
and Brazil. In Mexico, the Company expanded its retail pharmacy
business from the operation of 39 pharmacies to 150
pharmacies. In Brazil, the Company acquired Drogasmil, a
pharmacy chain through which the Company operates over 100
pharmacies. These investments had a positive impact on the
Company’s net sales and gross profit, which increased 12.4% and 23.4%,
respectively, for the year ended December 31, 2008, as compared to the
year ended December 31, 2007. However, these investments led to
an increase in its operating expenses, from Ps.1,424 million for the year
ended December 31, 2007 to Ps.2,104 million for the year ended December
31, 2008, or 47.7%, as a result of higher payroll and other operating
expenses related to its retail pharmacy business. The Company’s
comprehensive financing cost, net, also increased significantly, from
Ps.17.8 million for the year ended December 31, 2007 to Ps.181.1 million
for the year ended December 31, 2008, primarily as a result of the
interest-bearing liabilities that the Company incurred in connection with
the acquisition of Drogasmil. The Company’s tax provisions also
increased, from Ps.188.2 million for the year ended December 31, 2007 to
Ps.302.5 million for the year ended December 31, 2008, or 60.7%, as a
result of the acquisition in Brazil and the expansion in Mexico of its
retail pharmacy business. As a result of the factors described in this
paragraph, the Company’s net income decreased from Ps.905.1 million for
the year ended December 31, 2007, to Ps.595.1 million for the year ended
December
31, 2008.
|
|
Grupo
Casa Saba, S.A.B. de C.V.
|
||
|
(Name
of Registrant as Specified in Charter)
|
|
Date
|
June
30, 2009
|
By:
|
/s/
Gabriel Saba D'jamus
|
|
|
Name:
|
|
Gabriel
Saba D'jamus
|
||
|
Title:
|
Chief
Executive Officer
|